Literature DB >> 29162605

Changes in High-Density Lipoprotein Cholesterol Efflux Capacity After Bariatric Surgery Are Procedure Dependent.

Sean P Heffron1, Bing-Xue Lin2, Manish Parikh2, Bianca Scolaro2, Steven J Adelman2, Heidi L Collins2, Jeffrey S Berger2, Edward A Fisher2.   

Abstract

OBJECTIVE: High-density lipoprotein cholesterol efflux capacity (CEC) is inversely associated with incident cardiovascular events, independent of high-density lipoprotein cholesterol. Obesity is often characterized by impaired high-density lipoprotein function. However, the effects of different bariatric surgical techniques on CEC have not been compared. This study sought to determine the effects of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on CEC. APPROACH AND
RESULTS: We prospectively studied severely obese, nondiabetic, premenopausal Hispanic women not using lipid medications undergoing RYGB (n=31) or SG (n=36). Subjects were examined before and at 6 and 12 months after surgery. There were no differences in baseline characteristics between surgical groups. Preoperative CEC correlated most strongly with Apo A1 (apolipoprotein A1) concentration but did not correlate with body mass index, waist:hip, high-sensitivity C-reactive protein, or measures of insulin resistance. After 6 months, SG produced superior response in high-density lipoprotein cholesterol and Apo A1 quantity, as well as global and non-ABCA1 (ATP-binding cassette transporter A1)-mediated CEC (P=0.048, P=0.018, respectively) versus RYGB. In multivariable regression models, only procedure type was predictive of changes in CEC (P=0.05). At 12 months after SG, CEC was equivalent to that of normal body mass index control subjects, whereas it remained impaired after RYGB.
CONCLUSIONS: SG and RYGB produce similar weight loss, but contrasting effects on CEC. These findings may be relevant in discussions about the type of procedure that is most appropriate for a particular obese patient. Further study of the mechanisms underlying these changes may lead to improved understanding of the factors governing CEC and potential therapeutic interventions to maximally reduce cardiovascular disease risk in both obese and nonobese patients.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  bariatric surgery; gastric bypass; obesity; sleeve gastrectomy; weight loss

Mesh:

Substances:

Year:  2017        PMID: 29162605      PMCID: PMC5746465          DOI: 10.1161/ATVBAHA.117.310102

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  46 in total

Review 1.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

Review 2.  Multiple actions of high-density lipoprotein.

Authors:  Matilda Florentin; Evangelos N Liberopoulos; Anthony S Wierzbicki; Dimitri P Mikhailidis
Journal:  Curr Opin Cardiol       Date:  2008-07       Impact factor: 2.161

3.  Laparoscopic sleeve gastrectomy leads the U.S. utilization of bariatric surgery at academic medical centers.

Authors:  J Esteban Varela; Ninh T Nguyen
Journal:  Surg Obes Relat Dis       Date:  2015-02-12       Impact factor: 4.734

4.  High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese women.

Authors:  Edward Vazquez; Amar A Sethi; Lita Freeman; Gloria Zalos; Hira Chaudhry; Erin Haser; Brittany O Aicher; Angel Aponte; Marjan Gucek; Gregory J Kato; Myron A Waclawiw; Alan T Remaley; Richard O Cannon
Journal:  Am J Cardiol       Date:  2011-11-19       Impact factor: 2.778

5.  Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study.

Authors:  Chaoqun Liu; Yuan Zhang; Ding Ding; Xinrui Li; Yunou Yang; Qing Li; Yuanzhu Zheng; Dongliang Wang; Wenhua Ling
Journal:  Atherosclerosis       Date:  2015-11-10       Impact factor: 5.162

6.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Authors:  Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

7.  Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome.

Authors:  Amit V Khera; John S Millar; Giacomo Ruotolo; Ming-Dauh Wang; Daniel J Rader
Journal:  Eur Heart J       Date:  2015-06-25       Impact factor: 29.983

8.  The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages.

Authors:  Margarita de la Llera-Moya; Denise Drazul-Schrader; Bela F Asztalos; Marina Cuchel; Daniel J Rader; George H Rothblat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01-14       Impact factor: 8.311

9.  C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells.

Authors:  Xinwen Wang; Dan Liao; Uddalak Bharadwaj; Min Li; Qizhi Yao; Changyi Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-12-20       Impact factor: 8.311

10.  The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women.

Authors:  P D Wood; M L Stefanick; P T Williams; W L Haskell
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

View more
  15 in total

Review 1.  Unexplained reciprocal regulation of diabetes and lipoproteins.

Authors:  Sei Higuchi; M Concepción Izquierdo; Rebecca A Haeusler
Journal:  Curr Opin Lipidol       Date:  2018-06       Impact factor: 4.776

Review 2.  High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus.

Authors:  Yi He; Vishal Kothari; Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-02       Impact factor: 8.311

Review 3.  Treatment of Obesity in Mitigating Metabolic Risk.

Authors:  Sean P Heffron; Johnathon S Parham; Jay Pendse; José O Alemán
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

4.  Reversal of NAFLD After VSG Is Independent of Weight-Loss but RYGB Offers More Efficacy When Maintained on a High-Fat Diet.

Authors:  Ankita Srivastava; Matthew Stevenson; Jenny Lee; Christopher Hall; Thomas Palaia; Chaohui Lisa Zhao; Raymond Lau; Collin Brathwaite; Louis Ragolia
Journal:  Obes Surg       Date:  2022-04-14       Impact factor: 3.479

Review 5.  Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors.

Authors:  John A Bostrom; Beth Mottel; Sean P Heffron
Journal:  Curr Atheroscler Rep       Date:  2021-08-05       Impact factor: 5.113

Review 6.  The Endothelium Is Both a Target and a Barrier of HDL's Protective Functions.

Authors:  Jérôme Robert; Elena Osto; Arnold von Eckardstein
Journal:  Cells       Date:  2021-04-28       Impact factor: 6.600

7.  Beneficial changes on plasma apolipoproteins A and B, high density lipoproteins and oxidized low density lipoproteins in obese women after bariatric surgery: comparison between gastric bypass and sleeve gastrectomy.

Authors:  J M Gómez-Martin; J A Balsa; E Aracil; M Cuadrado-Ayuso; M Rosillo; G De la Peña; M A Lasunción; H F Escobar-Morreale; J I Botella-Carretero
Journal:  Lipids Health Dis       Date:  2018-06-20       Impact factor: 3.876

8.  Correlates and Predictors of Cerebrospinal Fluid Cholesterol Efflux Capacity from Neural Cells, a Family of Biomarkers for Cholesterol Epidemiology in Alzheimer's Disease.

Authors:  Eleonora Cipollari; Hannah J Szapary; Antonino Picataggi; Jeffrey T Billheimer; Catherine A Lyssenko; Gui-Shuang Ying; Leslie M Shaw; Mitchel A Kling; Rima Kaddurah-Daouk; Daniel J Rader; Domenico Praticò; Nicholas N Lyssenko
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.160

9.  Bariatric Surgery Improves HDL Function Examined by ApoA1 Exchange Rate and Cholesterol Efflux Capacity in Patients with Obesity and Type 2 Diabetes.

Authors:  Shuhui Wang Lorkowski; Gregory Brubaker; Daniel M Rotroff; Sangeeta R Kashyap; Deepak L Bhatt; Steven E Nissen; Philip R Schauer; Ali Aminian; Jonathan D Smith
Journal:  Biomolecules       Date:  2020-04-04

Review 10.  High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential.

Authors:  Anne Jomard; Elena Osto
Journal:  Front Cardiovasc Med       Date:  2020-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.